Work

Beyond Hormone Receptor Positivity: Prognostic Value of ER, PR, and Ki-67 Expression Levels in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: A Multicenter Real-World Study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background and Objectives: Clinical outcomes remain heterogeneous in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. We evaluated the prognostic relevance and incremental prognostic value of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression beyond clinical and treatment-related factors. Materials and Methods: This multicenter retrospective study included 568 patients treated with ribociclib- or palbociclib-based therapy between 2019 and 2024. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier and Cox regression analyses. The incremental prognostic value of ER, PR, and Ki-67 was assessed using nested Cox models with identical baseline clinical covariates and patient samples. Additional spline and exploratory cut-off analyses were performed. Results: Median PFS and OS were 29.23 and 44.43 months, respectively. Liver metastasis was independently associated with shorter PFS (HR 1.77, 95% CI 1.27–2.48; p = 0.001) and OS (HR 1.80, 95% CI 1.24–2.61; p = 0.002). Lung metastasis and prior endocrine therapy were independently associated with shorter PFS, whereas older age and prior endocrine therapy were associated with shorter OS. Although higher PR and lower Ki-67 expression were associated with longer PFS in univariable analyses, higher Ki-67 expression was independently associated with shorter PFS in the multivariable model (HR 1.008, p = 0.025), whereas ER and PR were not significantly associated with PFS or OS. Adding ER, PR, and Ki-67 to baseline clinical models did not significantly improve model fit for PFS (p = 0.087) or OS (p = 0.320). No significant nonlinear associations were identified, and exploratory cut-offs demonstrated limited stability. Exploratory subgroup analyses suggested incremental prognostic value in first-line treatment (p = 0.003), although the treatment-line interaction was not significant. Conclusions: Ki-67 showed an independent association with PFS, although the combined incremental prognostic value of ER, PR, and Ki-67 beyond clinical factors was limited. Further prospective studies are warranted to clarify their clinical utility.
Source: Medicina
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,654
OpenAlex ID: W7236750005
FWCI:
Cites: 26
Cited by:
Related to: 10